Hans Lilja

Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios.

J. Oesterling, H. Lilja, U. Stenman, 1995, The Journal of urology.

Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease.

H. Lilja, M. Karp, K. Irjala, 2002, Clinical chemistry.

Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.

A. Haese*, H. Lilja, M. Graefen, 2000, The Journal of urology.

Cancer-associated changes in the expression of TMPRSS2-ERG, PCA3, and SPINK1 in histologically benign tissue from cancerous vs noncancerous prostatectomy specimens.

A. Bjartell, Leni Kauko, P. Helo, 2014, Urology.

Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum.

H. Lilja, T. Piironen, K. Pettersson, 1998, Urology.

Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial.

J. Hugosson, R. Godtman, M. Månsson, 2024, European urology.